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Goals for immunization in older adults may differ from
those in young adults and children, in whom complete pre-
vention of disease is the objective. Often, reduced hospi-
talization and death but also averting exacerbation of
underlying chronic illness, functional decline, and frailty
are important goals in the older age group. Because of the
effect of age on dendritic cell function, T cell-mediated im-
mune suppression, reduced proliferative capacity of T cells,
and other immune responses, the efficacy of vaccines often
wanes with advanced age. This article summarizes the dis-
cussion and proceedings of a workshop organized by the
Association of Specialty Professors, the Infectious Diseases
Society of America, the American Geriatrics Society, the
National Institute on Aging, and the National Institute of
Allergy and Infectious Diseases. Leading researchers and
clinicians in the fields of immunology, epidemiology, infec-
tious diseases, geriatrics, and gerontology reviewed the cur-
rent status of vaccines in older adults, identified knowledge
gaps, and suggest priority areas for future research. The
goal of the workshop was to identify what is known about
immunizations (efficacy, effect, and current schedule) in
older adults and to recommend priorities for future re-
search. Investigation in the areas identified has the potential
to enhance understanding of the immune process in aging
individuals, inform vaccine development, and lead to more-
effective strategies to reduce the risk of vaccine-preventable
illness in older adults. J Am Geriatr Soc 58:765–776, 2010.
Key words: immunization; vaccination
Median life expectancy in the United States rosesteadily through the 20th century, from the age of
approximately 50 in 1900 to the current age of almost 80.
Much of the increase in longevity can be attributed to re-
duced infection-related deaths in children and young adults
achieved through sanitation, immunization, and antibiot-
ics. An aging population has resulted in people aged 65 and
older constituting the most rapidly growing segment of the
U.S. population. This is a global phenomenon, with median
life-expectancy predicted to rise into the 70s in most coun-
tries by 2050.1 Older adults are more vulnerable to most
infectious diseases, including those considered ‘‘vaccine
preventable’’2 (e.g., influenza),3 placing a large burden on
healthcare resources.4 To assess the current evidence base
and identify and prioritize research in the area of vaccine-
preventable illness in older adults, a workshop sponsored
by the John A. Hartford Foundation was held in Washing-
ton, D.C., in December 2008, bringing together members of
the immunology, infectious diseases, geriatric medicine, and
gerontology communities. The proceedings of this work-
shop are summarized in this manuscript. The meeting fo-
cused on the basic and translational science of vaccine
biology but did not address the real and important matters
of access, vaccine uptake, or population-based strategies
For the workshop attendees.
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(e.g., immunization of healthcare workers and close con-
tacts) that influence the rate of vaccine-preventable illness
in older adults.5
GOALS OF IMMUNIZATION IN OLDER ADULTS
Although the goal of immunization for most childhood ill-
nesses (e.g., measles, polio) is elimination of clinical disease,
this is often unrealistic for older adult populations with
diminished immunity and impaired vaccine responses. The
goals of immunization in older adults are to prevent serious
illness, hospitalization, and death, but benefits relating to
exacerbation of underlying chronic illness, functional de-
cline, and frailty are other worthy endpoints, although they
are rarely examined in clinical trials. These endpoints are
more difficult to measure and harder to specifically attribute
to the organism(s) targeted by vaccines, often leading to
conflicting evidence of vaccine efficacy in older adults. For
example, although some investigators have found that ad-
ministering the influenza vaccine to community-dwelling
individuals aged 65 and older leads to significant reductions
in risk of hospitalization for pneumonia or influenza,
and death,6 others have documented little or no effect,
particularly in those aged 70 and older with significant
comorbidities.7,8
Exacerbation of underlying illness is a major contrib-
utor to infection-related morbidity and mortality in older
adults, but the mechanisms that lead to adverse outcomes
have not been fully elucidated. Some data suggest that in-
flammation after an infectious illness is prolonged in older
adults, with significant elevations of serum amyloid A and
C-reactive protein that may contribute to triggering events
such as myocardial infarction and stroke.9 A few studies
suggest that vaccines can significantly reduce this risk.10,11
A major objective of preventive interventions in older
adults is the reduction of catastrophic disability, defined as
loss of independence in three or more activities of daily
living (ADLs).12 Nearly three-quarters of those experienc-
ing catastrophic disability have been hospitalized with
stroke, congestive heart failure, pneumonia, ischemic heart
disease, cancer, or hip fracture.12 Influenza and other viral
infections have been linked to catastrophic disability in
several studies.13,14 The degree of underlying comorbidity,
measures of functional reserve (e.g., walking speed), and
evidence of changes in adaptive immunity common, but not
universal, in advanced age predict risk of adverse outcomes
after vaccine-preventable illnesses. To better understand
vaccine responses in adults with frailty or advanced age,
clinical trials are needed that measure relevant risks and
outcomes in these populations. The benefit of vaccination
might not be consistently measurable in some studies, be-
cause the benefit of preventing catastrophic or other dis-
ability increases in older adults (e.g., because of the inability
to see decline in function because of low starting point on
available validated scales, i.e., a ‘‘floor’’ effect). It is impor-
tant that a means of measuring vaccine efficacy in frail
adults be addressed in the study of new vaccines.
EFFECTS OF AGING ON IMMUNE FUNCTION
Older individuals experience lower quantity and quality of
the immune response after immunization than young
adults15 as a result of disease- and age-related changes in
multiple aspects of the immune system. A complete review
of immune senescence is beyond the scope of this article, but
major aspects pertinent to vaccine responses are summa-
rized below, and the reader is referred to recent publications
for a more-complete review.16–18
Antigen-Presenting Cell Function
Antigen-presenting cells (APCs) are specialized cells that
present foreign substances and send out signals to T cells,
initiating an immune response. Although B cells, macro-
phages, and other cells can act as APCs, the major APC for
most vaccines is the dendritic cell (DC). DCs present an-
tigen and provide co-stimulation signals and cytokine that
drive T cell and B cell responses. The capacity for older DCs
to present antigen is well preserved, but aging (65) ap-
pears to alter cytokine production significantly19 and can
affect co-stimulation; pattern recognition receptors such as
Toll-like receptors (TLRs) typically trigger both. TLRs rec-
ognize microbial products (e.g., lipids, proteins, ribonucleic
acid, deoxyribonucleic acid); specifically, TLR9 recognizes
nucleic acid sequences and multiple cytosines and guanines
that are more common in viruses than mammalian cells.
Plasmacytoid DCs demonstrate poor upregulation of inter-
feron regulatory factor (IRF) 7 after TLR9 activation, and
greater oxidative stress contributes to this defect, but other
studies demonstrate that the age-associated defect in inter-
feron-alpha (IFNa) production is reversible. After aug-
menting the production of IFNa in older hosts, immune
function (as measured according to viral clearance) is sim-
ilar to that of young adult mice.20
Human studies of DCs are limited. In human peripheral
blood monocytes (from which DCs are derived) less surface
expression of TLR1/2 and agonist-induced tumor necrosis
factor-a and interleukin-6 production but unchanged
expression of TLR4 was demonstrated.19 TLR-induced
defects in cytokine production and expression of the
co-stimulatory molecule CD80 in human DCs appear more
extensive than previously observed in monocytes and
are highly associated with influenza vaccine antibody
response.19 Expression of PRAT4A, a protein associated
with TLR4 that is required for multiple TLR responses, is
also lower in older adults.21
T Cells and Adaptive Immunity
Studies of T cell immune senescence are most extensive in
mouse models that demonstrate some age-related changes
intrinsic to the T cell, but other mouse models are depen-
dent on the T cell residing in the older host.22 The produc-
tion of new naive T cells and their number and function in
the periphery declines with age, gradually, through adoles-
cence and early adulthood; the involution of the thymus
appears to be the major contributor to this change. Older
T cells respond less well to antigenic stimulation (reduced
proliferation and cytokine production) than young T cells.
Furthermore, poor B cell proliferation, germinal center for-
mation, and immunoglobin (Ig)G production to T-depen-
dent antigens evidence the ability of older T cells to assist B
cell responses to vaccines.23 Mouse studies also demon-
strate that the environment functionally inhibits young
T cells transferred into older hosts, perhaps because of
766 HIGH ET AL. APRIL 2010–VOL. 58, NO. 4 JAGS
demonstrated age-related increases in T-regulatory or other
cells that inhibit immune responses.24
Primate studies also suggest that intrinsic and extrinsic
factors contribute to poorer T cell function with age. The
naı̈ve T cell pool, those T cells not yet exposed to antigen
recognized by their specific T cell receptor, exhibits greater
cycling in older nonhuman primates in direct proportion to
the extent of depletion of naive T cells. This is consistent
with the ‘‘antagonistic pleiotropy’’ theory of agingFthat
the same mechanisms that provide advantages early in life
(e.g., maintenance of the naive T cell pool by low-level
cycling, perhaps in response to IL-7) tend to enhance the
loss of naive T cells by homeostatic proliferation and mem-
ory conversion late in life.25 Investigators have documented
several distinct types of age-related disturbances in T cells
that affect T cell homeostasis. Repertoire balance, the
breadth of antigens to which the T cell pool can respond, is
poorer with age, impairing the ability to respond to a pre-
viously unencountered pathogen26 (Figure 1). In the CD81
T cell compartment, there is a similar loss of diversity and
accumulation of a narrow repertoire of oligoclonal memory
T cells directed at viral pathogens that persist throughout
life (e.g., cytomegalovirus (CMV)). An expanded group of
senescent CD81 T cells directly correlates with poorer re-
sponses to vaccines,27,28 perhaps because of the inhibitory
cytokines produced by these senescent CD81 T cells. (See
Mechanisms Underlying Immune Senescence below.)
Human studies reveal age-related changes in T cell
function similar to those observed in rodent and nonhuman
primate models. These include contraction in T cell recep-
tor diversity and imbalance of functional T cell subsets, as
described above. Impaired T cell activation and signaling,
poor T cell proliferation, and aberrant gene expression is
also noted.29 The earliest epidemiological evidence of
poorer adaptive immunity is seen in people aged 50 to 60
with thymic demise, telomeric erosion in CD4 and CD8 T
cells, decline in CD8 naive and central memory T cells, and
oligoclonal expansion in the CD8 memory T cell compart-
ment that parallels the nonhuman primate studies outlined.
Although individuals aged 60 to 74 still have a reasonable
ability to respond to a diverse array of pathogens because of
a broad group of naive CD4 T cells30 and normal induction
of early activation markers in CD4 T cells, reduced pro-
liferative capacity of naive T cells has been observed. The T
cells are characteristic of activation-induced signatures that
feature overexpression of zinc-induced genes (metal-
lothioneins) and lack of a type I interferon signature.31 A
stable compartment of CD4 memory T cells remains, but
there is accumulation of end-stage effector CD8 T cells, loss
of the co-stimulatory protein CD28 on CD8 memory T
cells, and gain of negative regulatory receptors on CD8
memory T cells.28
Naive CD4 and CD8 T cell compartments are charac-
teristically greatly reduced after age 75, as is the repertoire
of naive CD4 T cells. Furthermore, poorer responsiveness
to T cell receptor stimuli with defects in proximal signaling,
less induction of activation markers, a contracted repertoire
of memory CD4 T cells, a predominance of end-stage
Figure 1. Conceptual models of age-related changes in T cell–dendritic cell interactions and T cell replication in older adults (A) and
lower production of the full diversity of the naive T cell repertoire (B). (A) Aging results in less signaling between antigen-presenting
cells and T cells, along with less interleukin-2 production, that may underlie impaired T cell proliferation. (B) Thymic involution and
greater homeostatic cycling within the naive T cell pool have been shown and may be a cause of less T cell diversity noted with older
age. Reprinted with permission.26
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effector CD8 T cells, and high expression of negative reg-
ulatory receptors (e.g., CD85j, killer cell Ig-like receptors,
and programmed death-1 (PD-1))32,33 are all characteristics
of the immune response of people aged 75 and older.
B Cells and Adaptive Immunity
B cell changes with age have also been examined in multiple
animal and human models. B cell proliferation does not
decrease in older mice, but there are reduced antigen-naive
and expanded antigen-experienced pools and a smaller an-
tibody repertoire with age. In mice, reduced efficiency in
class switching (e.g., from IgM to IgG) to produce high-
affinity antibodies is apparent with age; this process
requires activation-induced adenosine deaminase and tran-
scription factor E47, both of which are reduced in aged B
cells.
Dramatically greater rates of pneumonia and bacter-
emia due to encapsulated organisms that require antibody
production for clearance, B cell lymphomas, greater auto-
immune disease, and less proliferation to mitogens, with a
larger memory B cell population but smaller naive B cell
repertoire suggest changes in B cell function in humans aged
75 and older. Unlike in mice, the numbers of circulating
human B cells decline gradually over the age of 60, although
a direct cause-and-effect relationship between human B cell
decline and the greater incidence of invasive pneumococcal
disease in adults aged 50 and older, rather than other as-
pects of immune senescence or inherent defects resulting
from concomitant underlying disease, has not been estab-
lished. A comparison of immune parameters and in vitro
and in vivo immune responses in healthy older persons
(mean age 80) and healthy younger adults (physician train-
ees with a mean age of 30) found similar results in both
groups. Both groups showed vigorous responses to protein
and polysaccharide vaccines,34 suggesting that age alone




Oligoclonal Expansion of Inhibitory CD81 T Cells
A possible contributing factor to the accumulation of se-
nescent CD81 T cells that inhibit vaccine and other im-
mune responses is the presence of chronic infections such as
CMV. Unlike acute infection that is resolved and provides
limited support to T and B cell responses, persistent viral
infections lead to frequent reactivation of immune re-
sponses and the accumulation of oligoclonal CD81 cells
over time (Figure 2). These oligoclonal CD81 T cells have
less proliferation but produce high levels of immune inhib-
itory cytokines. CMV seropositivity and expansion of
oligoclonal, inhibitory CD81T cells are characteristics of
Figure 2. Immune response after acute (A) or chronic (B) viral infection. Acute viral infection results in limited expansion of immune
cells, viral clearance, and contraction of effector immune cells resulting in a stable memory compartment. Chronic viral infections
follow a similar early course but persist or reactivate, causing eventual expansion of a small number of clonal effector cells. These
oligoclonal, senescent T cells overproduce cytokine and suppress immune responses to new antigens. Reprinted26 with permission.
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the immune-senescent phenotype in humans, which is
highly correlated with impaired vaccine responses.27,28
Age-Associated Accumulation of Inhibitory Proteins on
the Cell Surface
Overexpression of inhibitory receptors, including PD-1 re-
ceptor and the killer cell lectin-like receptor G1, are seen in
older mice, but their role in poor vaccine responses is un-
known.35 In chronic viral infections (e.g., human immuno-
deficiency virus (HIV), hepatitis C), PD-1 negatively
regulates CD8 T cell responses, and PD-1 blockade rein-
vigorates immune responses against those viruses in mice
(unpublished data).
Reductions in Telomere Length
Telomeres are essential for chromosomal integrity and
completion of chromosomal replication and may play a
critical role in regulation of the replicative life span of
cells.36 Shorter telomere length in human lymphocytes with
cell division in vitro and with age in vivo has been observed
gradually with increasing age.37,38 Although senescent lym-
phocytes are associated with shorter telomeres, longer telo-
mere length often is associated with greater replicative
lifespan of lymphocytes in vitro.39 Despite these findings,
whether telomere erosion plays a causal role in age-asso-
ciated immune function decline remains to be determined.
EFFICACY OF CURRENTLY RECOMMENDED
VACCINES IN OLDER ADULTS
The Centers for Disease Control and Prevention’s (CDC’s)
Advisory Committee on Immunization Practices, a com-
mittee comprising vaccine experts that develops public
health recommendations for vaccine administration and
recommends a number of vaccines for adults based on age
(Figure 3). These recommendations are updated as needed.
At this workshop, the efficacy of influenza, pneumococcal
polysaccharide, and zoster vaccines was discussed; each is
briefly reviewed below. More-extensive reviews of the
individual vaccines are widely available in the published
literature.
Influenza
Influenza is one of the top 10 causes of death in older
adults.40 Individuals aged 65 and older are at high risk for
serious influenza-associated illness, and complications are
responsible for up to 10% of winter cardiopulmonary
deaths. An estimated 10% of annual pneumonia and influ-
enza deaths and 3% of all respiratory and circulatory
deaths are attributed to influenza, with 90% of these deaths
occurring in those aged 65 and older. A review of 31 studies
found that influenza vaccination had 50% to 80% efficacy
in preventing influenza illness in healthy adults, with high-
est efficacy in years with a good match between vaccine and
circulating strains,41 but the efficacy of influenza vaccines in
adults aged 65 and older and persons with chronic diseases
of the heart, lungs, and kidneys is a subject of intense con-
troversy. One clinical trial of healthy community dwelling
adults aged 60 and older reported vaccine efficacy of 60%
against laboratory-confirmed influenza, but there are no
clinical trials involving frail elderly persons and outcomes
of hospitalization or death. Some evidence indicates that the
antibody response to vaccination decreases with age.42
Most studies of vaccine effectiveness in older persons
have used observational data. There is considerable debate
about the interpretation of studies that have used large ad-
ministrative data and outcomes such as hospitalization or
deaths from pneumonia and influenza. Although some
studies suggest large decreases in hospitalizations and
deaths due to influenza vaccine, annual estimated influ-
enza-associated mortality has changed little over the last 2
decades, despite large increases in vaccine uptake.43 In ad-
dition, analysis of hospitalized elderly persons has revealed
marked differences in functional status between those who
were and were not immunized with influenza vaccine that
probably resulted in overestimation of vaccine efficacy.8 To
try to address some of these concerns, the CDC has begun a
cooperative group study to examine annual vaccine effec-
tiveness using a case–control design and medically attended
Figure 3. Centers for Disease Control and Prevention recommended adult immunization schedule according to vaccine and age
groupFUnited States 2009. Source: http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm.
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illness as the outcome. In the meantime, the official CDC
recommendation remains annual provision of influenza
vaccine to all adults aged 50 and older and all those likely to
transmit influenza to vulnerable older adults (e.g., family
members, close contacts, healthcare workers, and nursing
home staff). Known risks of the influenza vaccine are local
pain and a mild fever or a feeling of malaise.
Pneumococcal Polysaccharide Vaccine
Adults aged 65 and older are at high risk for pneumococcal
disease. Observational studies of pneumococcal poly-
saccharide vaccine (PPV) in older adults have consistently
demonstrated a lower risk of invasive pneumococcal dis-
ease (IPD), defined according to positive blood cultures, in
older adults with no immune-suppressive drugs or disease
(e.g., lymphoma) who receive PPV, but the efficacy in
immunocompromised hosts is less convincing.44–51 One
case–control study examined time since immunization in
different age groups and found a trend toward less efficacy
with older age (65) and time since vaccination.44 CDC
recommends a single immunization after age 65 (Figure 3).
This recommendation is based on evidence of waning effi-
cacy of PPV in people aged 85 and older and some evidence
in the literature that antibody responses are not boosted,
and are perhaps even blunted, with repeated dosing of
PPV.45 There are some preliminary data that suggest that
the antibody response to pneumococcal conjugate vaccine,
which is protein-linked, may be greater than the antibody
response to the current PPV in older adults.52
The efficacy of PPV for outcomes other than IPD in
older adults is uncertain. Clinical trials have not consis-
tently demonstrated a reduction in all-cause pneumonia
with PPV in adults aged 65 and older, perhaps because of
the many other causes of community-acquired pneumonia,
and it is generally believed that PPV does not reduce the risk
of nonbacteremic pneumococcal pneumonia.53–55 Studies
are needed to determine whether pneumococcal conjugate
vaccines can prevent nonbacteremic pneumococcal pneu-
monia, which is much more common than IPD. A random-
ized trial of a 13-valent conjugated pneumococcal vaccine
against PPV to prevent vaccine-type pneumococcal pneu-
monia is under way in 85,000 older adults in the Nether-
lands.56 Current side effects of PPV23 include mild redness
or pain where the vaccine was given, fever, and muscle
aches, with more-severe local reactions in less than 1% of
those vaccinated.
Zoster
The CDC also recommends vaccination against herpes
zoster, or shingles, a disease caused by reactivation and
multiplication of endogenous, latent varicella-zoster virus
(VZV) (Figure 3). Although the varicella vaccine against
chickenpox, usually administered to children before pri-
mary infection, has efficacy of 95% or greater and induces
herd immunity,57 vaccination against VZV in persons after
primary infection and prevention of zoster requires chang-
ing the host–virus relationship rather than preventing pri-
mary infection. Cell-mediated immunity is the major
determinant of the incidence and severity of herpes zoster.
Levels of cell-mediated immunity decline with advancing
age, corresponding with an age-related increase in the in-
cidence and severity of shingles, but levels of antibody to
VZV do not decline.58
The zoster vaccine, a live-virus vaccine, boosts the de-
clining level of preexisting cell-mediated immunity to the
virus, reducing the frequency and severity of shingles in
older adults. Studies of vaccine efficacy found burden of
illness, an overall measure of pain over time, was 65.5%
lower in individuals aged 60 to 69 and 55.4% lower in
those aged 70 and older. Pain that interfered with ADLs and
postherpetic neuralgia (PHN) was approximately two-
thirds less after vaccination.57 Incidence of disease 63.9%
less in the people aged 60 to 69 but only 37.6% less in those
aged 70 and older, whereas efficacy for PHN was preserved
with age and did not differ in the two groups.58
In addition to the CDC-recommended vaccinations
mentioned above, it is also recommended that adults aged
65 and older receive a tetanus booster shot every 10 years.
POTENTIAL FOR VACCINES DIRECTED AGAINST
PROBLEM ORGANISMS IN OLDER ADULTS
Clostridium difficile
Most people are exposed to Clostridium difficile; many do
not develop infection or symptomatic illness, but rates of C.
difficile disease in hospitalized patients tripled from 2000 to
2005, with the increase almost exclusively in adults aged 65
and older59 (Figure 4). C. difficile–related deaths more than
quadrupled in the United States from 1999 to 2004, and
nearly all deaths occur in older adults. C. difficile–attrib-
utable death rates were four times those of methicillin-
resistant Staphylococcus aureus (MRSA) and six times
those of all other intestinal infectious diseases combined.59
Nonantibiotic approaches to this antibiotic-induced disease
are sorely needed.
Several C. difficile toxins have been characterized, and
toxins A and B both result in diarrhea and colitis.60 Evi-
dence for protective immunity is seen in the fact that ap-
proximately two-thirds of the population has antitoxin
antibodies, which appear to be acquired early and main-
Figure 4. Rates of U.S. short-stay hospital discharges with Clos-
tridium difficile listed as any diagnosis by age. Reprinted from
McDonald LC, Owings M, Jernigan DB. Clostridium difficile
infection in patients discharged from US short-stay hospitals,
1996–2003. Emerg Infect Dis [serial on the Internet]. 2006 Mar
[May 15, 2009]. Available at http://www.cdc.gov/ncidod/EID/
vol12no03/05-1064.htm with permission.58
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tained throughout life. Serum IgG anti-toxin A levels are
high in asymptomatic carriers. Recurrent infection is com-
mon, and antibiotic therapy with metronidazole or van-
comycin may perpetuate vulnerability to recurrent
infection, especially in those with a defective immune re-
sponse.60 Antitoxin antibody levels are lower in those with
recurrent symptoms; conversely, higher levels are associated
with lower risk for recurrent diarrhea.61 Active and passive
immunity are both possible. Some promising data from
early studies using toxoid vaccine demonstrate strong an-
tibody responses,62 but larger controlled trials, particularly
in older adults with significant comorbidity, are needed.
Streptococcus agalactiae
Infection due to Streptococcus agalactiae, previously
known as Group B streptococcus (GBS), is most commonly
associated with disease in neonates due to maternal–fetal
transmission, but a substantial disease burden has also been
documented in adults aged 65 and older.63 Adults aged 65
and older have a rate of GBS infection five times as great as
those aged 15 to 64. The case-fatality rate for invasive GBS
in adults aged 65 and older is 9% to 10%, and 50% of all
invasive GBS-associated deaths occurred in this age group.
The incidence of invasive GBS disease in nonpregnant
adults increased 32% from 1999 to 2005, with more than
16,000 cases and 1,140 deaths in 2007 and an unknown but
much larger number of skin and soft-tissue infections.
Nearly all GBS infections in adults occur in persons with
underlying illnessFmost often diabetes mellitus, heart dis-
ease, or malignancy. Serotype distribution differs according
to age, with type V prevalent in older adults and type III in
newborns.63
A five-valent GBS conjugate vaccine theoretically could
prevent approximately 85% of invasive GBS disease in
adults. A number of candidate GBS conjugate vaccines are
in trials and have been found to elicit more than fourfold
increases in serum capsular polysaccharide-specific IgG in
80% to 100% of healthy adults younger than 50, including
two type V vaccines.64 One vaccine, a tetanus-toxoid-
linked GBS serotype V conjugate, resulted in a fourfold rise
in serum antibody titers in 76% of healthy older adults.65
Limited published data suggest that the GBS vaccines tested
to date are well tolerated.
Methicillin-Resistant Staphylococcus aureus
MRSA is a ubiquitous pathogen that can cause a broad
range of clinical conditions, including skin infection, pneu-
monia, and bacteremia. The rate of MRSA hospitalization
was three times as high in adults aged 65 and older as in any
age group.66 Immunity to S. aureus infections is character-
ized by high innate resistance to invasive staphylococcal
infection due to epidermal and mucosal surface barriers and
intact cellular, humoral, and innate immune host defenses.
Although serious infection has usually been dependent on
mechanical, immunological, and metabolic changes in host
status and most often seen in the past in healthcare settings,
community-associated MRSA is becoming increasingly
common.67
With no good evidence to suggest a clear mechanism of
immunity, there is no guidance on how to make a vaccine
against MRSA. Patients who recover from S. aureus infec-
tions are not immune and are at higher risk for re-infection;
thus, the typical immune response to S. aureus cannot be
expected to induce protective immunity. A logical approach
might be to target the cell-surface polysaccharides and cap-
sules that prevent opsonic killing by phagocytes, but clinical
trials of capsule vaccines have been unsuccessful, although
preclinical studies have shown that several vaccine candi-
dates to altered or normally concealed components of the
bacteria can induce protection from infection and serious
disease. For example, poly-N-acetyl b-1-6-glucosamine
(PNAG) is a surface polysaccharide on almost all strains
of S. aureus. Antibodies against a chemically modified ver-
sion of PNAG, prepared by reducing the level of N-ace-
tylation (deacetylated PNAG or dPNAG), had efficacy in a
few animal models.68 In addition, a fully human mono-
clonal antibody that can bind to native and dPNAG is op-
sonic against a variety of Staphylococcal strains and
improves survival in a mouse model of lethal infection.69
Despite the difficulties in developing an effective S.
aureus vaccine, two current candidate vaccines target sur-
face proteins of S. aureus in clinical trials. One product,
used for passive immunization, is a humanized monoclonal
antibody directed at lipoteichoic acid, a component of the S.
aureus cell wall; that compound has been examined only in
clinical trials enrolling neonates. The other candidate is a
vaccine for active immunization, V710, that targets iron
surface determinant B of S. aureus, induces strong antibody
responses in nonhuman primates,70 and is now being
used in a phase II clinical trial to reduce the risk of post-
operative complications in patients undergoing cardiotho-
racic surgery.
NEW APPROACHES TO BOOST VACCINE
RESPONSES IN OLDER ADULTS
Greater Antigen Dose Including Baculovirus-
Expressed Antigens
Although numerous studies of inactivated influenza vac-
cines demonstrate greater antibody responses with greater
dosage, few of these studies have included older adults; one
study in the 1960s, which was conducted in a retirement
community, suggested greater efficacy with a high-dose
vaccine.71 More-recent work with influenza vaccine in an
older population has determined that greater vaccine anti-
gen dose results in greater serum antibody responses, mu-
cosal antibody responses, and antibody responses to related
potential future influenza virus variants. Greater injection
site reactions were also noted but were modest.72
Greater antigen dose is difficult with the current vac-
cine or manufacturing process because it would require a
much greater capacity. A more-economical and -practical
way to produce high-dose vaccines would be to use influ-
enza component (hemagglutinin (HA) and neuraminidase)
vaccines derived using highly efficient processes. Baculovi-
rus-derived vaccines, or vaccines grown in Baculovirus,
against influenza have been evaluated widely, including in
studies in older adults with antigen doses up to nearly 10
times as high as HA or neuraminidase present in the current
vaccine.73–77 Recombinant HA appears to be well tolerated
and immunogenic, inducing a functional antibody, and
protective efficacy has been demonstrated in healthy adults
at levels similar to those of other inactivated influenza
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vaccines. Higher HA doses can result in higher titer antibody
responses in older adults. Baculovirus is used to infect insect
cells to produce the proteins; the technology is already in use
for human vaccines, and efficient protein production allows
greater supply with easy scale-up that does not require spe-
cialized facilities, and the substrate does not select receptor
variants. The use of insect cells may further reduce the risk
of egg-associated allergic reactions infrequently encountered
with the current vaccine, although because the correlates of
vaccine protection (laboratory markers of immune response
that accurately predict protection from disease) are not well
defined in older adults, particularly those with comorbidity,
it is difficult to definitively determine which subunits to in-
clude and subunit vaccines stimulate whether the most-pro-
tective immune responses.
TLR Agonists
TLR expressed by various immune cells, including DCs and
other APCs, recognize microbial substances. TLR agonist
binding results in activation of innate immunity, which in
turn can enhance adaptive immunity. Some TLR agonists
(TLR3, TLR4, TLR5, TLR7/8, TLR9) have shown promise
as vaccine adjuvants. Better responses might be possible by
combining two or more immune modulators that act syn-
ergistically through different pathways or on different cells
(e.g., TLR41TLR9), or provide physiochemical advantages
for delivering a stimulatory signal (e.g., alum1TLR agonist)
(Table 1).
CpG-oligodeoxynucleotide (CpG-ODN), a TLR9 ago-
nist, in combination with alum, has been shown to be a
highly effective adjuvant to several different antigens in
young healthy adults. Various dataFincluding effective-
ness in older mice and immune-compromised (low CD41T
cell count) HIV-positive patientsFsuggest that CpG also
might be effective in older adulst as an influenza vaccine
adjuvant. Defective CD41 T cells play an important role in
age-related decline in adaptive immunity,78 CD41 T cells
from young adult mice restore IgG responses when trans-
ferred into aged mice,79 and inflammatory cytokines in vivo
enhance defective CD41 T cell function in older mice.80
Murine studies have shown lower TLR expression and
function in older animals,81 but other studies substantiate
the ability of CpG-ODN to restore antitumor responses in
older mice.82 A number of other studies have validated the
effect with different forms of antigen.83–87 It appears that
matching a TLR to a specific pathogen is not required be-
cause there is considerable redundancy in these systems.
Thirty-seven, mostly phase I, published clinical trials
have tested CPG 7909 as an adjuvant, and strong augmen-
tation of antibody responses has been noted with a variety
of antigens; none of these trials were performed in older
humans (65). Enhanced T cell immunity has been dem-
onstrated with melanoma88 and hepatitis B virus vaccines89
in young adults. Furthermore, trials in healthy or HIV-
infected adults showed that CpG enhanced antibody re-
sponses with a commercial hepatitis B vaccine. Hepatitis B
antigen responses decline dramatically with age, starting at
approximately age 35.90 Trials of CpG-adjuvanted hepatitis
B vaccine could be tested in older adults as a proof of con-
cept for use of this novel adjuvant to improve immunogeni-
city of other vaccines in the elderly.
Mucosal Targeting
The majority of pathogens enter the body through mucosal
tissues, with two major routes for induction of mucosal
immune responses: gut-associated lymphoid tissue (GALT)
and nasal-associated lymphoid tissue (NALT). Studies in
mice demonstrate that NALT is preserved well into older
age and that delivering adjuvanted vaccine preparations
through the intranasal route is effective.91,92 A combination
of adjuvants was most effective and enhanced ovalbumin-
specific antibody response (plasma IgG and IgA and se-
creted IgA) and upregulated Th1- and Th2-type cytokine
production.
Blocking Inhibitory Receptors
T cell changes in older mice include more negative regu-
lators of T cell function, such as high expression of PD-1
receptor and KLRG1 on T cells.93 There are also changes
with age in negative regulatory pathways in humans, but
the precise connection between inhibitory pathways and
immunity is not clear. Blocking negative regulatory path-
ways could provide opportunities to manipulate the quality
of immunity in older people, and investigators are exam-
ining in vivo manipulation and depletion of Treg and




CD81 Cytotoxic T Lymphocytes
Determined According to Chromium Release Assay
CpG 11 1 11
Aluminum hydroxide 1   (1)
CpG1aluminum hydroxide 11111 11 1111
Lipid emulsions 11  11
CpG1lipids 1111 1111 111
Saponin 11  11
CpG1saponin 111 1111 111
ISCOMS 11111 1 111
CpG1ISCOMS 11111 11111 111

1 and  indicate degree of enhancement of response in mice over antigen alone when administered through the intramuscular route. Results derived with
various antigens and adjuvants were used to assign these general trends, which do not necessarily represent a given adjuvant or delivery system.
CpG 5 cytosine and guanine; ISCOMS 5 immune-stimulating complexes.
772 HIGH ET AL. APRIL 2010–VOL. 58, NO. 4 JAGS
blockade of inhibitory receptor pathways in vivo (unpub-
lished data). Because blockade of the PD-1 pathway has
therapeutic benefits in other settings,94,95 testing the effect
of targeting this pathway in older mice is of potential in-
terest.
CHALLENGES IN TRANSLATION OF NEW
VACCINES TO CLINICAL USE
The controlled conditions of animal models often fail to
translate to human communities. Important clinical out-
comes in older persons (e.g., inflammatory measures,
thrombotic complications, functional assessments, cata-
strophic disability) are not typically measured and must be
included in future studies. Longitudinal studies of immune
memory are needed to determine optimal timing of vaccine
administration (young adulthood, middle age, advanced
age?) to provide optimal protection in old age. A mixed-
effects model, a model used with dependent data, which
examines a group or cluster of people over a course of many
years investigating the fixed and random effects, may be the
best way to achieve some uniformity in future studies.
An additional difficulty in developing vaccines in adult
populations is performing vaccine efficacy studies in older
adults. Although the overall burden of disease is high be-
cause of the large numbers of older adults, the incidence of
disease is usually low, necessitating large, expensive trials.
The challenges of optimizing immunization for older
persons are important to public health and public policy.
Although pediatric immunization has been a spectacular
success (95%) built on a public–private partnership, only a
modest proportion (50–70%) of adult target populations
are immunized, with disparities according to income, race,
and ethnicity. Funding is a critical issue, with 30 million to
40 million adults without medical insurance and others
who face the barriers of copayments and other out-of-
pocket expenses. In addition, a public health perspective
may suggest that immunizing groups capable of transmis-
sion of disease to vulnerable seniors (seniors with multiple
comorbidities) will be more effective than immunizing se-
niors with limited immune response capacity, but this needs
to be tested in well-conducted trials.
PRIORITIES AND QUESTIONS FOR
FUTURE RESEARCH
General Questions
 At what age(s) do specific vaccines demonstrate waning
efficacy, and how does the diversity of the older pop-
ulation affect immunity? What is the interaction be-
tween age and functional status on the efficacy of a
vaccine?
 Given age-related declines in immunity and nascent ev-
idence of long-lived immunity for many vaccines (e.g.,
smallpox), at what younger stages of the life can and
should immunization be provided to have the greatest
effect on disease in older ages? What are the effects of
multiple vaccines over time?
 What are predictors or surrogate markers of vaccine
efficacy and failure, including the role of specific nutri-
tional deficiencies and genetics?
 What are the best means for measuring vaccine efficacy
in very frail adults?
Mechanisms
 What are the relative contributions of DC, T cell, and B
cell deficits in immune senescence? Are there common
factors (e.g., extrinsic influences) that cause these de-
fects, or are they cell specific (e.g., intrinsic)?
 What are the roles of chronic viral infection, inhibitory
cell surface markers, suppression by exhausted CD8
cells, and upregulation of other negative responses? Are
the deficits fixed or reversible?
 Are abundant Tregs a matter in age-related nonresponse
to vaccines? Are Treg quantity and quality results of
aging or comorbidity?
 Are there common mechanisms of immune exhaustion,
such as naive T cell overreplication or stem cell exhaus-
tion?
 Can boosting the innate immune system overcome T
cell and B cell deficits in humans?
 Are new adjuvants or delivery vehicles (e.g., TLR ago-
nists) and combinations useful in older adults, as shown
for murine models of immune senescence?
 What is the role of greater antigen? How much antigen
is needed to be effective while limiting reactogenicity?
Why does it work for some components and not others,
and what is the duration of response?
 How can other modalities of enhancing response or re-
ducing age-related inhibition (e.g., mucosal targeting,
blocking inhibitory receptors) be used and combined
with adjuvants and delivery vehicles?
Enhancing Available Cohorts and Resources
 What additional databases are available to determine
correlates of protection, surrogate markers of nonre-
sponse, and duration of response (i.e., can longitudinal
aging studies answer these questions)? Many were ini-
tiated before more-sophisticated immune response mea-
sures were known but could provide populations for
current study of older adults.
 Can longitudinal cohorts of men and women returning
from military service, who have received a variety of
vaccines, be useful to study kinetics of antibody and
immune decline to investigate appropriate timing of
vaccines?
 How can animal models be developed to mirror human
conditions (e.g., repeated influenza infection) rather
than studying only primary infection? What are the
most-representative functional assessments in older an-
imals that reflect functional status in humans? What
nondeath outcomes can be represented in animal mod-
els that might be important in older humans?
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